Reviewer’s report

Title: The impact of KRAS mutations on VEGF-A production and tumour vascular network

Version: 1 Date: 14 December 2012

Reviewer: Daniel Zicha

Reviewer’s report:

This manuscript presents a new, valid and convincing scientific contribution to our understanding of the mechanisms of KRAS mutation induced carcinogenesis with average general impact and interest to your readership. Their findings about more VEGF-A expression with K-ras ASP13 mutation in 3T3 cells and related changes in vivo should be discussed in comparison with similar results in colon carcinomas (e.g. Regulation of Vascular Endothelial Growth Factor by the Wnt and K-ras Pathways in Colonic Neoplasia, Xiaobo Zhang, John P. Gaspard and Daniel C. Chung, Cancer Res 2001;61:6050-6054.) and fairly extensive literature on bevacizumab, a monoclonal antibody targeting the vascular endothelial growth factor-A (VEGF) in cancer cells with K-ras mutations.

Minor spelling issues:
Abstract Paragraph1: Glycolitic should be glycolytic
Tumor growth patterns: “, T” should be “. T”

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Needs some language corrections before being published

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

I declare that I have no competing interests.